Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradation. Preclinical studies demonstrate that autophagy inhibition with hydroxychloroquine augments the anti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Vogl, Dan T, Stadtmauer, Edward A, Tan, Kay-See, Heitjan, Daniel F, Davis, Lisa E, Pontiggia, Laura, Rangwala, Reshma, Piao, Shengfu, Chang, Yunyoung C, Scott, Emma C, Paul, Thomas M, Nichols, Charles W, Porter, David L, Kaplan, Janeen, Mallon, Gayle, Bradner, James E, Amaravadi, Ravi K
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2014
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4203515/
https://ncbi.nlm.nih.gov/pubmed/24991834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/auto.29264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados